Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06562660

The Effect of Mask Combined With High Flow Oxygen on Preoxygenation During Induction of General Anesthesia in Obese Patients

There is a risk of airway-related incidents during anaesthesia associated with obesity. High-flow nasal oxygen is advocated for perioperative preoxygenation in obese patients to reduce airway adverse reactions. However, there have been no reports on whether smoking behaviors have an impact on obese men's Apnoeic oxygenation with high-flow nasal.This study compared the effects of smoking on the duration of safe apnoea times in obese males.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Obese Behavior Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms Smoking

Age range

18 year–80 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

About this study

All patients were were divided into two groups based on smoking status: smokers(S groups), and never smokers(NS groups). Those in the smoking group were current smokers, while those in the nonsmoking group had never smoked. Both groups of patients were induced with intravenous anesthesia and received 5 minutes of high flow nasal oxygen (60 L min) prior to induction.After induction of anaesthesia, the patients were apnoeic until peripheral oxygen saturation decreased to 95 %.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants ranged in age from 18 to 80 with BMI≥30 kg/m2.
  • Participants are male obese patients undergoing elective non-thoracic surgery

Exclusion criteria

  • patients were kept awake during the intubation due to cervical spine pathology.
  • Patients with unstable hemodynamics.
  • Patients with airway inflammatory diseases, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary fibrosis and cystic fibrosis.
  • Patients with upper respiratory infection and nasal blockage.
  • Patients with Hypersensitivity to the drug.

Treatment and study plan

apnoeic

Device

In group S, High-Flow Nasal Oxygen was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 95 %.

Primary outcomes

  1. the safe apnoea times

    Time frame: 5-minute

    Investigators will record the time of oxygen saturation drop to 95 % during intubation.

Secondary outcomes

  1. the Pao2 levels

    Time frame: 5-minute

    the Pao2 levels after 5-minute pre oxygenation with high flow nasal oxygen in two groups of patients.

Study contacts

Contact information is provided by the study sponsor or research team.

huabing wang

CONTACT

[email protected]

+8618538706687

jiaqiang zhang

CONTACT

[email protected]

+8613937121360

Sponsors and collaborators

Lead sponsor

Henan Provincial People's Hospital

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Aug 20, 2024
Registry last updated
Sep 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.